Nucleix highlights data for urine test in detecting bladder cancer

By staff writers

June 30, 2020 -- Liquid biopsy firm Nucleix said that its methylation-based Bladder EpiCheck urine test produced strong results for detecting high-risk, non-muscle invasive bladder cancer (NMIBC) in a study published online June 11 in the Journal of Clinical Pathology.

In a study of 374 patients at Agostino Gemelli University Hospital in Rome, Italy, the firm's methylation-based assay outperformed cytology alone and yielded high sensitivity, specificity, and negative predictive value, Nucleix said. The findings support the use of Bladder EpiCheck to detect recurrence of NMIBC in patients who have undergone instillations, according to the vendor.

AI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancer
A new liquid biopsy method based on DNA methylation and powered by artificial intelligence (AI) demonstrated promising performance at classifying brain...
Google reports pathology AI helps predict survival in cancer patients
Google scientists reported proof-of-concept data for their artificial intelligence (AI) system in analyzing pathology images and predicting survival of...
KDx bladder cancer urine test gets breakthrough designation
KDx Diagnostics said that its URO17 immunocytochemical biomarker test for detecting bladder cancer recurrence has received the breakthrough device designation...
LabCorp launches Qiagen's FGFR test for bladder cancer
LabCorp announced on May 10 that it has begun offering Qiagen's therascreen companion diagnostic for detecting FGFR mutations in bladder cancer.
Natera touts liquid biopsy in bladder cancer
Results from Natera's prospective study validating its Signatera circulating tumor DNA (ctDNA) test in urothelial bladder cancer were published online...

Copyright © 2020

Last Updated ls 6/30/2020 2:47:52 PM